<DOC>
	<DOCNO>NCT01734278</DOCNO>
	<brief_summary>The purpose observational study evaluate use short term safety Asenapine ( Sycrest ) real-life usage Mental Health Trust Setting United Kingdom ( UK ) National Health Service ( NHS ) . The study carry independently Drug Safety Research Unit ( DSRU ) Southampton , although funded Merck , manufacturer Sycrest .</brief_summary>
	<brief_title>Observational Post-Authorisation Safety Study Asenapine ( Sycrest )</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Patients study questionnaire contain useful information return Patients provide consent Patients within select institution ( example prison ) Patients commence treatment date market launch ( confirm ) study start Enrolled patient baseline 12week questionnaire return blank ( contain clinical information ) Enrolled patient psychiatrist , designate member clinical care team , study facilitator DSRU report patient take never prescribe asenapine Enrolled patient evidence suggest duplication patient Enrolled patient informed write verbal notification receive DSRU indicate longer wish participate stage study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>